{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:58:56Z","timestamp":1772801936565,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81402040"],"award-info":[{"award-number":["81402040"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81272739"],"award-info":[{"award-number":["81272739"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.cllc.2015.03.006","type":"journal-article","created":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T13:43:01Z","timestamp":1428241381000},"page":"e55-e66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non\u2013Small-Cell Lung Cancer Cells"],"prefix":"10.1016","volume":"16","author":[{"given":"Jia-Tao","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Cheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Qiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Qing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu-Lu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Ping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2015.03.006_bib1","first-page":"225","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cllc.2015.03.006_bib2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.1101637","article-title":"Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways","volume":"305","author":"Sordella","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.cllc.2015.03.006_bib3","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/1097-0142(19920901)70:5<1102::AID-CNCR2820700514>3.0.CO;2-5","article-title":"New aspects in the staging of lung cancer: prospective validation of the International Union Against Cancer TNM classification","volume":"70","author":"Bulzebruck","year":"1992","journal-title":"Cancer"},{"issue":"suppl 4","key":"10.1016\/j.cllc.2015.03.006_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1634\/theoncologist.7-suppl_4-2","article-title":"Why the epidermal growth factor receptor? The rationale for cancer therapy","volume":"7","author":"Baselga","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2015.03.006_bib5","first-page":"515","article-title":"Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression","volume":"3","author":"Rusch","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2015.03.006_bib6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cllc.2015.03.006_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2011.04.022","article-title":"The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non\u2013small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor","volume":"75","author":"Kobayashi","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2015.03.006_bib8","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non\u2013small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2015.03.006_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non\u2013small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2015.03.006_bib10","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2015.03.006_bib11","first-page":"2053","article-title":"Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor","volume":"6","author":"Ciardiello","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2015.03.006_bib12","first-page":"4885","article-title":"Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase","volume":"6","author":"Sirotnak","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2015.03.006_bib13","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.2005.05.1474","article-title":"Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non\u2013small-cell lung\u00a0cancer: the Tarceva Lung Cancer Investigation Trial","volume":"25","author":"Gatzemeier","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2015.03.006_bib14","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2004.08.001","article-title":"Gefitinib in combination with gemcitabine and cisplatin in advanced non\u2013small-cell lung cancer: a phase III trial\u2014INTACT 1","volume":"22","author":"Giaccone","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2015.03.006_bib15","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel\u00a0and carboplatin in advanced non\u2013small-cell lung cancer: a phase III trial\u2014INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2015.03.006_bib16","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non\u2013small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2015.03.006_bib17","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1126\/science.290.5497.1717","article-title":"Autophagy as a regulated pathway of cellular degradation","volume":"290","author":"Klionsky","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.cllc.2015.03.006_bib18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev.immunol.021908.132537","article-title":"Enhancing immunity through autophagy","volume":"27","author":"Munz","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.cllc.2015.03.006_bib19","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cllc.2015.03.006_bib20","doi-asserted-by":"crossref","first-page":"9349","DOI":"10.1158\/0008-5472.CAN-06-1597","article-title":"Autophagy in cancer: good, bad, or both?","volume":"66","author":"Hippert","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2015.03.006_bib21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12032-009-9397-3","article-title":"Inhibition of autophagy by 3-MA potentiates cisplatin-induced apoptosis in esophageal squamous cell carcinoma cells","volume":"28","author":"Liu","year":"2011","journal-title":"Med Oncol"},{"key":"10.1016\/j.cllc.2015.03.006_bib22","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/ijc.24030","article-title":"Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells","volume":"124","author":"Shingu","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cllc.2015.03.006_bib23","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.3390\/molecules19044924","article-title":"The synergistic biologic activity of oleanolic and ursolic acids in complex with hydroxypropyl-gamma-cyclodextrin","volume":"19","author":"Soica","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.cllc.2015.03.006_bib24","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1365-2125.2004.02082.x","article-title":"Population pharmacokinetics of total and unbound plasma cisplatin in adult patients","volume":"57","author":"Urien","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cllc.2015.03.006_bib25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2010.01.028","article-title":"Methods in mammalian autophagy research","volume":"140","author":"Mizushima","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.cllc.2015.03.006_bib26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3892\/or.2013.2474","article-title":"Enhanced autophagic flux by endoplasmic reticulum stress in human hepatocellular carcinoma cells contributes to the maintenance of cell viability","volume":"30","author":"Ma","year":"2013","journal-title":"Oncol Rep"},{"key":"10.1016\/j.cllc.2015.03.006_bib27","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4161\/cbt.19292","article-title":"Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells","volume":"13","author":"Ohta","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.cllc.2015.03.006_bib28","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1200\/JCO.2005.02.857","article-title":"Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non\u2013small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib","volume":"23","author":"Eberhard","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2015.03.006_bib29","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1200\/JCO.2011.40.1315","article-title":"Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial","volume":"30","author":"Janne","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2015.03.006_bib30","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/JTO.0b013e3182021ff5","article-title":"Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?","volume":"6","author":"Tsai","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2015.03.006_bib31","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1158\/1078-0432.CCR-12-2621","article-title":"Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells","volume":"19","author":"Yamaguchi","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2015.03.006_bib32","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1158\/1078-0432.CCR-10-2634","article-title":"Principles and current strategies for targeting autophagy for cancer treatment","volume":"17","author":"Amaravadi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2015.03.006_bib33","doi-asserted-by":"crossref","first-page":"e18691","DOI":"10.1371\/journal.pone.0018691","article-title":"EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells","volume":"6","author":"Han","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.cllc.2015.03.006_bib34","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1158\/0008-5472.CAN-07-0562","article-title":"Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy","volume":"68","author":"Apel","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2015.03.006_bib35","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3816\/CLC.2006.n.021","article-title":"Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non\u2013small-cell lung cancer","volume":"7","author":"Davies","year":"2006","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2015.03.006_bib36","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4161\/auto.6083","article-title":"Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells","volume":"4","author":"Akar","year":"2008","journal-title":"Autophagy"},{"key":"10.1016\/j.cllc.2015.03.006_bib37","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cell.2005.07.002","article-title":"Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy","volume":"122","author":"Pattingre","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.cllc.2015.03.006_bib38","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4161\/auto.6788","article-title":"Dual role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation","volume":"4","author":"Wei","year":"2008","journal-title":"Autophagy"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730415000819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730415000819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:04:42Z","timestamp":1761505482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730415000819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S1525730415000819"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2015.03.006","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non\u2013Small-Cell Lung Cancer Cells","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2015.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}